Nektar Therapeutics announced that on May 18, 2022, the interim assessment committee reviewed interim efficacy and safety data from the ongoing Phase 2 double blinded, placebo-controlled study of NKTR-358 in 280 patients with systemic lupus erythematosus. The study is being conducted by Eli Lilly and Company in partnership with Nektar Therapeutics. The IAC reviewed unblinded interim data from approximately 60% of patients who completed the 24-week treatment period.

Following review of the data and based upon pre-specified criteria, the IAC recommended that the Phase 2 study continue to completion without modification. On May 19, 2022, Lilly informed Nektar of the IAC's assessment and recommendation. Pursuant to the IAC's recommendation, the Phase 2 study will continue as planned to completion.

No further unblinding of study data will occur.